Edition:
United States

Oxford BioMedica PLC (OXB.L)

OXB.L on London Stock Exchange

5.35GBp
23 Mar 2017
Change (% chg)

0.12 (+2.29%)
Prev Close
5.23
Open
5.47
Day's High
5.47
Day's Low
5.20
Volume
1,803,493
Avg. Vol
4,844,965
52-wk High
6.80
52-wk Low
2.98

Latest Key Developments (Source: Significant Developments)

Oxford biomedica says FY EBITDA loss reduced to £7.1 mln
Thursday, 16 Mar 2017 03:13am EDT 

Oxford Biomedica Plc : Fy EBITDA loss reduced to £7.1 million .Fy gross income increased by 64% to £30.8 million.  Full Article

Oxford biomedica says Trovax shown to induce beneficial anti-tumour immune responses
Friday, 24 Feb 2017 02:28am EST 

Oxford Biomedica Plc : Cyclophosphamide and Trovax independently shown to induce highly beneficial anti-tumour immune responses .Both drugs resulting in significantly prolonged survival of advanced colorectal cancer patients.  Full Article

Oxford Biomedica says Chief Development Officer Blake to leave in Aug
Thursday, 12 May 2016 02:11am EDT 

Oxford Biomedica Plc : Announces that Dr Paul Blake will leave group when his current contract expires at end of August 2016. .Blake was appointed to Oxford Biomedica's board as a non-executive director in January 2010 and subsequently he became chief development officer in September 2014..  Full Article

Oxford Biomedica PLC secures $50 million loan with oberland capital
Friday, 1 May 2015 02:00am EDT 

Oxford Biomedica PLC:Says that it has secured a $50 million loan facility from a subsidiary of Oberland Capital Healthcare.The funds will be used to invest in the Group's capacity expansion to enable it to deliver on commitments under its manufacturing agreement with Novartis and for pipeline advancements and product acquisitions.  Full Article

More From Around the Web

BRIEF-Oxford biomedica says Trovax shown to induce beneficial anti-tumour immune responses

* Cyclophosphamide and Trovax independently shown to induce highly beneficial anti-tumour immune responses